Advertisement
Advertisement
U.S. markets open in 1 hour 19 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Sinovac Biotech Ltd. (SVA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.470.00 (0.00%)
At close: 9:31AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.47
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's Range6.47 - 6.47
52 Week Range6.47 - 6.47
VolumeN/A
Avg. Volume0
Market Cap642.437M
Beta (5Y Monthly)0.05
PE Ratio (TTM)6.66
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
98% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SVA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • N/A
    The Argus Innovation Model PortfolioThe United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where costs are lower. Yet the U.S. economy, even during the pandemic, has expanded to record levels. If U.S. corporations weren't innovating, the domestic economy would not be growing and capital would not be flooding into the country. Consider that U.S. GDP was approximately $1 trillion in 1930 but nearly $23 trillion at the end of 1H21. That's growth of 23-times. Meanwhile, the U.S. population has grown less than three-times during that time span, to 320 million from 120 million. The delta between GDP growth and population growth has been driven, in large part, by innovation. In addition, the value of listed corporations on U.S. stock exchanges at the end of 2020 was approximately $41 trillion, according to SIFMA, representing 38% of global equity market capitalization, while U.S. GDP represented only 26% of global GDP. The current low level of interest rates and the relatively high level of the dollar both attest to the confidence that global investors have in the innovative U.S. economy.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Bloomberg

    China Vaccine Diplomacy Wavers as Nations Seek Western Shots

    (Bloomberg) -- In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWhy the Gaza Strip May Be the City of the

  • Reuters

    Rebuffed by Bolsonaro, Brazil medical institute to sell vaccines abroad

    Brazil's Butantan biomedical institute is in talks to sell a locally manufactured COVID-19 vaccine developed by China's Sinovac to other countries in South America and Africa, as the federal government has not ordered more of the shots. Butantan Director Dimas Covas said on Wednesday that the institute also has contracts to supply the vaccine directly to Brazilian states. Butantan is currently producing the shot developed by Sinovac Biotech Ltd in the Sao Paulo state using inputs imported from China, but it aims to complete a factory for 100% local production by early next year.

  • Reuters

    UPDATE 2-Sinovac in talks about setting up South Africa vaccine production

    China's Sinovac Biotech is in talks about setting up a vaccine production facility in South Africa to supply the African continent with shots against a range of diseases, the chief executive of its local partner said on Friday. Numolux Group CEO Hilton Klein made the comments at the launch of the South African leg of a global Phase III trial of Sinovac's COVID-19 vaccine in children and adolescents.

Advertisement
Advertisement